cdk4 6i abemaciclib  (MedChemExpress)

Journal: bioRxiv

Article Title: CDK4/6 inhibition sensitizes breast cancer to NK cell therapy by inducing immune-interactive surface proteins

doi: 10.64898/2026.04.19.719504

Figure Lengend Snippet: ( A ) Representative flow cytometry plots showing surface expression of indicated NK cell-activating and inhibiting signals in a PDO158 treated with 1 μM abemaciclib or vehicle control for 5 days. ( B ) Quantification of surface marker expression across 11 PDOs treated as in (A). n=3. ***p < 0.001, ****p < 0.0001 (two-way ANOVA). ( C ) Pie chart showing the proportion of PDOs that upregulated stress ligands and ICAM-1 after CDK4/6i treatment based on data in (B).

Article Snippet: Small molecule inhibitors, including CDK4/6i abemaciclib and ribociclib, PI3K/mTORi gedatolisib, and NFkB inhibitor BMS-345541 were purchased from AdooQ, MedChemExpress, and Selleckchem.

Techniques: Flow Cytometry, Expressing, Control, Marker

Journal: bioRxiv

Article Title: CDK4/6 inhibition sensitizes breast cancer to NK cell therapy by inducing immune-interactive surface proteins

doi: 10.64898/2026.04.19.719504

Figure Lengend Snippet: ( A, B ) Schematic of in vivo experiments administering CDK4/6i and NK cells sequentially (A) or concurrently (B). For sequential treatment (experiments 1 and 2, C-F), mice were pretreated with abemaciclib for 7-11 days, followed by a single NK cell infusion (10×10⁶ cells/injection). For concurrent treatment (experiment 3, G-H), mice were pretreated with abemaciclib for one week, and abemaciclib and NK cells (10×10⁶ cells/injection, weekly) were administered simultaneously. ( C ) Experiment 1, sequential treatment. Tumor growth curves in PDX-bearing mice treated with abemaciclib (75 mg/kg, daily) and NK92 cells. The treatment schedule is as shown in (A). n = 5 mice/group. Statistical significance calculated using 2-way ANOVA with Tukey’s post-test. ( D ) Corresponding survival curves for the experiment in (C). The Log-rank (Mantel-Cox) test was used to compare the combo and vehicle groups. ( E-F ) Tumor growth and survival in Experiment 2 with sequential treatment. The treatment scheme is shown in (A). Doses and analyses as in (C-D). n = 5 mice/group. ( G-H ) Tumor growth and survival in Experiment 3 with concurrent treatment. The treatment scheme is shown in (B). Doses and analyses as in (C-D). n = 5 mice/group.

Article Snippet: Small molecule inhibitors, including CDK4/6i abemaciclib and ribociclib, PI3K/mTORi gedatolisib, and NFkB inhibitor BMS-345541 were purchased from AdooQ, MedChemExpress, and Selleckchem.

Techniques: In Vivo, Injection

Journal: Heliyon

Article Title: CDK4/6i enhances the antitumor effect of PD1 antibody by promoting TLS formation in ovarian cancer

doi: 10.1016/j.heliyon.2023.e19760

Figure Lengend Snippet: Volcanic maps of differentially expressed genes between control and CDK4/6i groups (A). Volcanic maps of differentially expressed genes between control and α-PD1 groups (B). Volcanic maps of differentially expressed genes between control and Combined treatment groups (C). The hierarchical clustering analysis was used to classify different regulation patterns of gene expression, and the regulation patterns of gene expression in the same group were similar (D). GO enrichment analyses of downregulated (E) and upregulated (F) genes between combination group and control group. Venn diagram displayed downregulated and upregulated intersecting genes (G, H). The scale of fold change was used to make heat map to display the intersection genes between three treatment groups and the control group (I).

Article Snippet: Abemaciclib, a selective CDK4/6i, was purchased from MCE (New Jersey, NJ, USA).

Techniques: Control, Gene Expression